TWI BIOTECHNOLOGY, INC.
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
- Conditions
- Generalized Epidermolysis Bullosa Simplex
- Interventions
- Drug: Vehicle
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06073132
- Locations
- 🇮🇳
Sri Madhusudan Sai Institute of Medical Science, Muddenahalli, Karnataka, India
🇮🇳Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
🇺🇸Mission dermatology Center, Rancho Santa Margarita, California, United States
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05580042
- Locations
- 🇺🇸
Yale Center for Clinical Investigation, New Haven, Connecticut, United States
Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04468425
- Locations
- 🇨🇦
Syneos Health Facility, Québec, Canada
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
- Conditions
- EGFR Inhibitor-Induced Skin Rash
- Interventions
- Drug: AC-701 Topical Gel 0.3%Other: Placebo Gel
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT04239846
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Chang Gung Memorial Hospital, Taoyuan, Taiwan
A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03468322
- Locations
- 🇨🇳
Mackay Memorial Hospital, Hsinchu, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
- Prev
- 1
- 2
- Next